Drug Trial Radar · NCT05253053
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Apr 13, 2022
Primary completion
Aug 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and TNBC).
Conditions
- Advanced Solid Tumor
- Cholangiocarcinoma
- Biliary Tract Cancer
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Prostate Cancer
- Thyroid Cancer
- Gastric Cancer
- Gallbladder Cancer
Interventions
TT-00420Drug
TT-00420 tablet will be administered orally once daily per protocol defined schedule.
Combination Product: AtezolizumabDrug
Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
Combination Product: Nab-PaclitaxelDrug
Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 30 days from the last dose
- Dose limiting toxicity (DLT)Time frame: Up to 21 days from the first dose
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Fudan Univisity Shanghai Cancer Center
Shanghai, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
Shandong Cancer Hospital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.